Navigation Links
Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
Date:1/15/2009

    ANTONY, France, January 15 /PRNewswire-FirstCall/ --

       EUR millions           2007          07/06         2008        08/07
                           EUR     % sales % change   EUR    % sales % change
                        millions                    millions

    Southern Europe (1)   32.0       75       14      36.4     73       14
    Other EU Countries     9.7       22       17      11.3     23       17
    (2)
    Other markets          1.4        3       10      2.0       4       45
    SLIT                  34.6       80       21      40.4     81       17
    SCIT                   7.1       17       4       7.5      15       6
    Other products         1.4        3      (25)     1.8       4       32
    Total Q4 sales        43.1       100      15      49.7     100      15
    Southern Europe (1)   109.2      74       17     124.9     73       14
    Other EU countries    32.5       22       16      38.5     23       18
    (2)
    Other markets          5.4        4       11      7.5       4       38
    SLIT                  116.5      79       21     137.9     81       18
    SCIT                  24.9       17       3       26.3     15       6
    Other products         5.7        4      (7)      6.7       4       16
    Cumulative 12-month   147.1      100      16     170.9     100      16
    sales

    (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included
    Sales growth and financial position, 2009 outlook

4th quarter sales continued to register strong growth in all markets (up 15%, after 15% in 2007). The performance of non-EU markets in particular was remarkable during the quarter, as throughout the whole year. The sub-lingual route remained the main driver of this growth with an 18% increase over the financial year.

Overall, 2008 sales totalled EUR 170.9 million, an increase of 16%, in line with the strong growth consistently achieved since 2003 (ave
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
2. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
3. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
4. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
7. BIO 2008: Germany on Cutting Edge in Biomanufacturing
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Commencement 2008: Student innovation could improve data storage, magnetic sensors
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...v. 23, 2009 In a provocative new study, a Univers...oxide emissions the major cause of global warming...collapses or society builds the equivalent of one ...nlikely that there will be any substantial near-te...n carbon dioxide emission rates," says the new pap...
(Date:11/23/2009)...romises ultra-fast communication, computation and ...n. But trying to use quantum states as carriers of...w two physicists have shown, mathematically, how t...nication, while keeping the information intact. Th...ical Review Letters and highlighted with a Viewpo...
(Date:11/23/2009)...E,Nev.,Nov.23/PRNewswire-FirstCall/--PDLBioPharma,...sestablishedNovember27,2009astheex-dividenddatefor...ngfromthesecuritizationtransactioncompletedonNovem...allstockholdersofrecordontherecorddate,December1,2...ividendat$1.67pershareofcommonstockforpurposesofth...
(Date:11/23/2009)...,Nov.23/PRNewswire-FirstCall/--NeogenCorporation(N....D.,waselectedtoNeogen,sBoardofDirectorsatthecompa...erhasmorethan40yearsofexperienceinthefood,agricult...tprofessorofagriculturaleconomicsatVirginiaTechUni...edStateschiefagriculturenegotiatorwiththerankofamb...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2
...ific (NYSE: BSX ) today announced special items ...uarter. The Company plans to release its first qu...ompany disclosed last month, the Court of Appeals ...s decision that Johnson & Johnson,s (J&J) ...e Boston Scientific,s patent and that the patent i...
...gnostics,Incorporated (NYSE: DGX ) today announc...osed federal government investigation related to c...anufacturing subsidiary closed,voluntarily in 2006... since,its investigation began in 2004. , Ques...civil investigation.,While the company disagrees w...
...announced today that it,has completed the formatio...ment its existing group of Senior Advisers. NexBi... of DAS181 (Fludase(R)), an investigational drug,c...Bio throughout the clinical,development of this no...ced,product development to address the threat of a...
Other Biology Technology:Boston Scientific Announces First Quarter Special Items 2Boston Scientific Announces First Quarter Special Items 3Boston Scientific Announces First Quarter Special Items 4Boston Scientific Announces First Quarter Special Items 5Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 3NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 4
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Prostate cancer gives a new outlook on life 58853 1Prostate cancer gives a new outlook on life 58853 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 1University of Washington receives 2425 million to create Northwest Genomics Center 10256 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 3University of Washington receives 2425 million to create Northwest Genomics Center 10256 4Focused Radiation Protects Tumor Patients Brain Function 58850 1Focused Radiation Protects Tumor Patients Brain Function 58850 2
... in response to higher global temperatures may be ...count plants, ability to adjust to changing condit...onal Laboratory. , In a Perspectives paper publish...tes ORNL findings suggesting that about 9 percent ... the acclimation of plants included in the model. ...
...bage-eating moth may one day provide a safer, targ...y, researchers say. , , They compared the abilit... transposons, to insert themselves into a cell,s D...e cell resistant to damage from radiation therapy....o 10 times better than the other circular pieces o...
...nia, Los Angeles have defined conditions associate...n almost a third of breast cancer survivors, accor...ncer Research. , The key to their fatigue stems ...hese studies identify a biological basis for persi...ted by inflammation," said Michael Irwin, M.D., di...
Other Biology News:Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Inflammation markers identify fatigue in breast cancer survivors 2
EDTA Solution (pH 8.0) (0.5 M) from BioVision
Rat Anti-Mouse Limitin Monoclonal Antibody, Unconjugated, Clone 183727 from R&D Systems
Normal Human Serum from CHEMICON
Human HGF, Unconjugated from R&D Systems
Biology Products: